A

ATAI Life Sciences NV
D

ATAI

7.37500
USD
-0.02
(-0.27%)
قبل الجلسة
حجم التداول
300
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
2,735,126,934
المقالات
المزيد

العنوان: AtaiBeckley Inc

القطاع: الرعاية الصحية
الصناعة: Biotechnology
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.